The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial
de Zeeuw, Dick × Bekker, Pirow Henkel, Elena Hasslacher, Christopher Gouni-Berthold, Ioanna Mehling, Heidrun Potarca, Antonia Tesar, Vladimir Heerspink, Hiddo J Lambers Schall, Thomas J Bammens, Bert #
The lancet. Diabetes & endocrinology vol:3 issue:9 pages:687-696
Patients with type 2 diabetes and nephropathy have high cardiorenal morbidity and mortality despite optimum treatment including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Residual risk is related to residual albuminuria. We assessed whether CCX140-B, a selective inhibitor of C-C chemokine receptor type 2 (CCR2), could further reduce albuminuria when given in addition to standard care, including ACE inhibitors or ARBs.